BackgroundImmunoglobulin A nephropathy (IgAN) has a high incidence rate and a poor prognosis. Currently, no ideal treatment is available for this disease. Despite some reports on the use of telitacicept in IgAN, studies with a treatment duration of 24 weeks or longer remain limited, and data on its combination with glucocorticoids are currently lacking.MethodsThis retrospective cohort study enrolled 136 individuals diagnosed with IgAN via renal biopsy who exhibited 24-h urinary protein excretion